Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial

被引：0

作者：

Shumack, Stephen ^{[1
]}

Blauvelt, Andrew ^{[2
]}

Iversen, Lars ^{[3
]}

McBride, Sandy ^{[4
]}

Gooderham, Melinda ^{[5
,6
]}

Staubach-Renz, Petra ^{[7
]}

Yamauchi, Paul ^{[8
,9
]}

Staelens, Fabienne ^{[10
]}

Vanvoorden, Veerle ^{[10
]}

White, Katy ^{[10
]}

Gisondi, Paolo ^{[11
]}

机构：

[1] St George Dermatol & Skin Canc Ctr, Kogarah, NSW, Australia

[2] Oregon Med Res Ctr, Portland, OR USA

[3] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark

[4] Royal Free London NHS Fdn Trust, London, England

[5] Queens Univ, SKiN Ctr Dermatol, Peterborough, ON, Canada

[6] Prob Med Res, Peterborough, ON, Canada

[7] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Mainz, Germany

[8] Dermatol Inst & Skin Care Ctr, Santa Monica, CA USA

[9] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA USA

[10] UCB Pharma, Brussels, Belgium

[11] Univ Hosp Verona, Verona, Italy

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：17 / 18

页数：2

共 50 条

[1] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial
Kern, Johannes S.
Feldman, Steven R.
Gottlieb, Alice B.
Soung, Jennifer
Augustin, Matthias
Gisondi, Paolo
Peterson, Luke
Vanvoorden, Veerle
Ciaravino, Valerie
Gomez, Natalie Nunez
Warren, Richard B.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 19
[2] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
Eyerich, Kilian
Gottlieb, Alice B.
Piaserico, Stefano
Beissert, Stefan
Gooderham, Melinda
Kirby, Brian
Tilt, Nicola
Madden, Cynthia
Wiegratz, Susanne
de Cuyper, Dirk
Elewski, Boni
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
[3] Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Eyerich, Kilian
Gottlieb, Alice B.
Piaserico, Stefano
Beissert, Stefan
Gooderham, Melinda
Kirby, Brian
Tilt, Nicola
Madden, Cynthia
Wiegratz, Susanne
de Cuyper, Dirk
Merola, Joseph F.
Elewski, Boni
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4467 - 4469
[4] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
Feldman, Steven R.
Gottlieb, Alice B.
Soung, Jennifer
Augustin, Matthias
Gisondi, Paolo
Peterson, Luke
Vanvoorden, Veerle
Ciaravino, Valerie
Gomez, Natalie Nunez
Warren, Richard B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
[5] Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials
Strober, Bruce
Warren, Richard B.
Foley, Peter
Gooderham, Melinda
Thaci, Diamant
Cullen, Eva
Cioffi, Christopher
Peterson, Luke
Madden, Cynthia
Armstrong, April
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB76 - AB76
[6] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
Lebwohl, Mark
Ghoreschi, Kamran
Strober, Bruce
Eyerich, Kilian
Cather, Jennifer
Wang, Maggie
Cioffi, Christopher
Deherder, Delphine
Staelens, Fabienne
Gomez, Natalie Nunez
Puig, Luis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
[7] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the openlabel extension period of the BE RADIANT phase 3b trial
Strober, Bruce
Paul, Carle
Blauvelt, Andrew
Thaci, Diamant
Elewski, Boni
White, Katy
Vanvoorden, Veerle
Deherder, Delphine
Staelens, Fabienne
Eyerich, Kilian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB146 - AB146
[8] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
Strober, Bruce
Paul, Carle
Blauvelt, Andrew
Thaci, Diamant
Elewski, Boni
White, Katy
Vanvoorden, Veerle
Deherder, Delphine
Staelens, Fabienne
Spelman, Lynda
Eyerich, Kilian
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 14
[9] Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study
Youn, Sang Woong
Jo, Seong Jin
Park, Chul Jong
Kim, Dong Hyun
Shin, Bong Seok
Jeong, Ki Heon
Bang, Chul Hwan
Cross, Nancy
Thirlwell, Jackie
Hoepken, Bengt
JOURNAL OF DERMATOLOGY, 2024,
[10] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober, Bruce
Paul, Carle
Blauvelt, Andrew
Thaci, Diamant
Puig, Luis
Lebwohl, Mark
White, Katy
Vanvoorden, Veerle
Deherder, Delphine
Gomez, Natalie Nunez
Eyerich, Kilian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 486 - 495

← 1 2 3 4 5 →